Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients

Critical Reviews in Oncology/Hematology

Volumn 71, Issue 3, 2009, Pages 214-221

  Jakobsen, Jan Nyrop ^a   Herrstedt, Jørn ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiemetics; Cancer; Chemotherapy; Elderly; Nausea; Vomiting

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOCETAXEL; DOLASETRON MESILATE; ERLOTINIB; FLUOROURACIL; FLUOXETINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMATINIB; IRINOTECAN; ONDANSETRON; OPIATE; OXALIPLATIN; PALONOSETRON; PAROXETINE; PHENYTOIN; TROPISETRON; UNINDEXED DRUG;

AGE; ALCOHOL CONSUMPTION; ANTICIPATORY NAUSEA AND VOMITING; BREAST CANCER; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; COMORBIDITY; CONSTIPATION; DEMENTIA; DRUG INHIBITION; DRUG METABOLISM; ELDERLY CARE; ELECTROLYTE DISTURBANCE; EUPHORIA; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FLUSHING; HEADACHE; HUMAN; INSOMNIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OVARY CANCER; PATIENT COMPLIANCE; PATIENT MONITORING; POLYPHARMACY; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CANCER; PRURITUS; PSYCHOLOGICAL ASPECT; REVIEW; SEX DIFFERENCE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; DRUG INTERACTIONS; HUMANS; NAUSEA; NEOPLASMS; POLYPHARMACY; RISK FACTORS; VOMITING;

EID: 67651245077     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.12.006     Document Type: Review

References (42)

1. Boyle P. The globalisation of cancer. Lancet 368 (2006) 629-630
2. Rosner S.A., and Stampfer M.J. The heart-breaking news about tobacco: it's all bad. Lancet 368 (2006) 621-622
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics 2007. CA Cancer J Clin 57 (2007) 43-66
4. Yancik R., and Ries L.A.G. Cancer in older persons: an international issue in an ageing world. Semin Oncol 31 (2004) 128-136
5. Coates A., Abraham S., Kaye S.B., et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19 (1983) 203-208
6. Griffin A.M., Butow P.N., Coates A.S., et al. On the receiving end V-patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7 (1996) 189-195
7. Bloechl-Daum B., Deuson R.R., Mavros P., Hansen M., and Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24 (2006) 4472-4478
8. Chen L., de Moor C.A., Eisenberg P., Ming E.E., and Hu H. Chemotherapy-induced nausea and vomiting-incidence and impact of patient quality of life at community oncology settings. Support Care Cancer 15 (2007) 497-503
9. Grunberg S.M., Osoba D., Hesketh P.J., et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 13 (2005) 80-84
10. Popescu R.A., Norman A., Ross P.J., et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17 (1999) 2412-2418
11. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas or solid tumours. Eur J Cancer 42 (2006) 2433-2453
12. Tonato M., Roila M., and Del Favero M. Methodology of antiemetic trials: a review. Ann Oncol 2 (1991) 107-114
13. Doherty K.M. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3 (1999) 113-119
14. Roila F., Tonato M., Basurto C., et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone vs. metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5 (1987) 141-149
15. D'Acquisto R.W., Tyson L.B., Gralla R.J., et al. The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc ASCO 5 (1986) 257
16. Andrykowski M.A., Redd W.H., and Hatfield A.K. Development of anticipatory nausea: a prospective analysis. J Consult Clin Psychol 53 (1985) 447-454
17. Roscoe J.A., Bushunow P., Morrow G.R., et al. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 101 (2004) 2701-2708
18. Ritter H.L., Gralla R.J., Hall S.W., et al. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer Invest 16 (1998) 87-93
19. Yancik R. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 6 (1996) 399-412
20. Gross C.P., Guo Z., McAvay G.J., Allore H.G., Young M., and Tinetti M.E. Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatrics Soc 54 (2006) 1898-1904
21. 3-receptor antagonists in the first 24 hours. Gerontology 51 (2005) 287-296
22. Yancik R. Cancer burden in the aged. Cancer 80 (1997) 1273-1283
23. Jorgensen T., Johansson S., Kennerfalk A., et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 35 (2001) 1004-1009
24. Blower P., de Witt R., Goodin S., and Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized?. Clin Rev Oncol Hematol 55 (2005) 117-142
25. Banning M. Enhancing older people's concordance with taking their medication. Br J Nurs 13 (2004) 669-674
26. Brenner B.M., Meyer T.W., and Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Eng J Med 307 (1982) 652-659
27. Aapro M., Extermann M., and Repetto L. Evaluation of the elderly with cancer. Ann Oncol 11 (2000) 223-229
28. Catterson M.L., Preskorn S.H., and Martin R.L. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatr Clin North Am 20 (1997) 205-218
29. Kaiser R., Sezer O., Papies A., et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20 (2002) 2805-2811
30. De Witte J.L., Schoenmaekers B., Sessler D.I., et al. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 92 (2001) 1319-1321
31. Blum R.A., Majumdar A., McCrea J., et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25 (2003) 1407-1419
32. Gilbert C.J., Petros W.P., Vredenburgh J., et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 42 (1998) 497-503
33. Cagnoni P.J., Matthes S., Day T.C., et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin. Bone Marrow Transplant 24 (1999) 1-4
34. Herrstedt J., and Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 101 (2007) 143-150
35. Navari R.M., and Koeller J.M. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 37 (2003) 1276-1286
36. Depré M., Van Hecken A., Oeyen M., et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 61 (2005) 341-346
37. Nygren P., Hande K., Petty K.J., et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 55 (2005) 609-616
38. Gridelli C. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. Drugs Aging 21 (2004) 825-832
39. Antiemetic Subcommittee of MASCC. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17 (2006) 20-28
40. Kris M.G., Hesketh P.J., Sommerfield M.R., et al. ASCO guidelines for antiemetics in oncology: update 2006. J Clin Oncol 24 (2006) 2932-2947
41. Herrstedt J., and Roila F. ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 19 Suppl. 2 (2008) ii110-ii112
42. Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. Nov 27, 2008. [Epub ahead of print].